Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5656 AL 5670

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections

Danysz W, Parsons CG.

Br J Pharmacol. 2012 Sep;167(2):324-52. doi: 10.1111/j.1476-5381.2012.02057.x.

Modulating metals as a therapeutic strategy for Alzheimer's disease

Hung LW, Barnham KJ.

Future Med Chem. 2012 May;4(8):955-69. doi: 10.4155/fmc.12.32.

Manipulation of microglial activity as a therapy for Alzheimer's disease

Tan B, Choi RH, Chin TJ, Kaur C, Ling EA.

Front Biosci (Schol Ed). 2012 Jun 1;4(4):1402-12. doi: 10.2741/s342.

Novel disease-modifying therapies for Alzheimer's disease

Jiang T, Yu JT, Tan L.

J Alzheimers Dis. 2012;31(3):475-92. doi: 10.3233/JAD-2012-120640.

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study

Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, Kanetaka H, Iwamoto T.

Geriatr Gerontol Int. 2013 Jan;13(1):90-7. doi: 10.1111/j.1447-0594.2012.00866.x. Epub 2012 Jun 4.

Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy

Zheng H, Fridkin M, Youdim MB.

Curr Drug Targets. 2012 Jul;13(8):1089-106. doi: 10.2174/138945012802009026.

Pleiotropic protective effects of phytochemicals in Alzheimer's disease

Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G.

Oxid Med Cell Longev. 2012;2012:386527. doi: 10.1155/2012/386527. Epub 2012 May 28.

The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation

Anand A, Banik A, Thakur K, Masters CL.

Curr Alzheimer Res. 2012 Nov;9(9):1010-29. doi: 10.2174/156720512803569055.

Effects of polyphenols on brain ageing and Alzheimer's disease: focus on mitochondria

Schaffer S, Asseburg H, Kuntz S, Muller WE, Eckert GP.

Mol Neurobiol. 2012 Aug;46(1):161-78. doi: 10.1007/s12035-012-8282-9. Epub 2012 Jun 17.

Colombia at the centre of preclinical AD research

Lancet Neurol. 2012 Jul;11(7):567. doi: 10.1016/S1474-4422(12)70144-8.

γ-Secretase modulator in Alzheimer's disease: shifting the end

Xia W, Wong ST, Hanlon E, Morin P.

J Alzheimers Dis. 2012;31(4):685-96. doi: 10.3233/JAD-2012-120751.

A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial

Molloy DW, Standish TI, Zhou Q, Guyatt G; DARAD Study Group.

Int J Geriatr Psychiatry. 2013 May;28(5):463-70. doi: 10.1002/gps.3846. Epub 2012 Jun 21.

Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia

Allegri RF, Guekht A.

Drugs Today (Barc). 2012 Apr;48 Suppl A:25-41. doi: 10.1358/dot.2012.48(Suppl.A).1739721.

The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery

Sharma HS, Castellani RJ, Smith MA, Sharma A.

Int Rev Neurobiol. 2012;102:47-90. doi: 10.1016/B978-0-12-386986-9.00003-X.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias